Page 83 - 2021年18期

[ 4 ] JIANG N，JINGWEI L，WANG H，et al. Ginsenoside 20 UPLC-ESI-MS/MS assay for 20（S）-protopanaxadiol and
（S）-protopanaxadiol attenuates depressive-like behaviour pharmacokinetic application of its two formulations in
and neuroinflammation in chronic unpredictable mild rats[J]. Anal Sci，2010，26（7）：749-753.
stress-induced depressive rats[J]. Behav Brain Res，2020， [14] ZHAO X E，LV T，ZHU S，et al. Dual ultrasonic-assisted
393：112710. dispersive liquid-liquid microextraction coupled with mi-
[ 5 ] ZHANG H，PAN D，WU X，et al. Platelet protease activa- crowave-assisted derivatization for simultaneous determi-
ted receptor 1 is involved in the hemostatic effect of 20 nation of 20（S）-protopanaxadiol and 20（S）-protopanaxa-
（S）-protopanaxadiol by regulating calcium signaling[J]. triol by ultra high performance liquid chromatography-tan-
Front Pharmacol，2020，11：549150. dem mass spectrometry[J]. J Chromatogr A，2016，1437：
[ 6 ] CHEN M Y，SHAO L，ZHANG W，et al. Metabolic analy- 49-57.
sis of Panax notoginseng saponins with gut microbiota- [15] LING J，YU Y，FENG J，et al. Restricted access magnetic
mediated biotransformation by HPLC-DAD-Q-TOF-MS/MS core-mesoporous shell microspheres with C8-modified in-
[J]. J Pharm Biomed Anal，2018，150：199-207. terior pore walls for the identification of 20（S）-proto-
[ 7 ] YANG L，WANG C，XIE X，et al. LC-MS/MS determina- panaxadiol metabolites in rat plasma using UPLC-Q-TOF-
tion of ginsenoside compound K and its metabolite 20 MS/MS[J]. J Chromatogr B Analyt Technol Biomed Life
（S）-protopanaxadiol in human plasma and urine：applica- Sci，2017，1054：73-79.
tions in a clinical study[J]. Bioanalysis，2019，11（5）：365- [16] BAO Y，WANG Q，TANG P. Lithium adduct as precursor
380. ion for sensitive and rapid quantification of 20（S）-proto-
[ 8 ] JIN S，JEON J，LEE S，et al. Detection of 13 ginsenosides panaxadiol in rat plasma by liquid chromatography/qua-
（Rb1，Rb2，Rc，Rd，Re，Rf，Rg1，Rg3，Rh2，F1，compound K， drupole linear ion trap mass spectrometry and application
20（S）-protopanaxadiol，and 20（S）-protopanaxatriol）in to rat pharmacokinetic study[J]. J Mass Spectrom，2013，
human plasma and application of the analytical method to 48（3）：399-405.
human pharmacokinetic studies following two week-re- [17] LI J Q，WANG J F，LI J，et al. Simultaneous determination
peated administration of red ginseng extract[J]. Molecules， of 20（S）-protopanaxadiol and its three metabolites in rat
2019，24（14）：2618. plasma by LC-MS/MS：application to their pharmacokine-
[ 9 ] LING J，YU Y，ZHU J，et al. A highly sensitive HPLC- tic studies[J]. Biomed Chromatogr，2018，32（8）：e4252.
MS/MS method for quantification of 20（S）-protopanaxa- [18] 国家药典委员会.中华人民共和国药典：四部[S]. 2020年
diol in human plasma and its application in phase Ⅱ A 版.北京：中国医药科技出版社，2020：466-472.
clinical trial of a novel antidepressant agent[J]. J Chromatogr [19] VOELKER T，MENG M. Handbook of LC-MS bioanaly-
B Analyt Technol Biomed Life Sci，2016，1031：214-220. sis[M].Shoboken，New Jersey：John Wiley & Sons，2013：
[10] 金鑫，张振海，孙娥，等.原人参二醇脂质立方液晶纳米粒 170.
在大鼠体内的药动学研究[J].中国中药杂志，2013，38 [20] CHEN L，ZHOU L，HUANG J，et al. Single- and multi-
（2）：263-268. ple-dose trials to determine the pharmacokinetics，safety，
[11] XIE F，LI S，CHENG Z，et al. Determination of 20 tolerability，and sex effect of oral ginsenoside compound
（S）-protopanaxadiol in human plasma by HPLC-MS/MS： k in healthy chinese volunteers[J]. Front Pharmacol，2018，
application to a pharmacokinetic study[J]. Acta Pharmaceutica 8：965.
Sinica B，2013，3（6）：385-391. [21] Food and Drug Administration. Bioanalytical method vali-
[12] WANG W，SHAO Y，MA S，et al. Determination of 20 dation guidance for industry[S]. 2018-05.
（S）-protopanaxadiol ocotillol type epimers in rat plasma [22] European Medicines Agency. Guideline on bioanalytical
by liquid chromatography tandem mass spectrometry[J]. J method validation[S]. 2011-07-21.
Chromatogr B Analyt Technol Biomed Life Sci，2012， （收稿日期：2021-05-25 修回日期：2021-08-26）
887/888：19-24. （编辑：邹丽娟）
[13] HAN M，CHEN J，CHEN S，et al. Development of a

中国药房 2021年第32卷第18期 China Pharmacy 2021 Vol. 32 No. 18 ·2253 ·